Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.62 |
| ▸ | CDC42BPB | Q9Y5S2 | 9/20 | 0.62 |
| ▸ | CDC42BPA | Q5VT25 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674338 | 1.00 | LRRK2 (0.66) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL30543157 | 0.79 | LRRK2 (1.00) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL3561097 | 0.79 | LRRK2 (0.66) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL2105745 | 0.79 | LRRK2 (1.00) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL16190651 | 0.79 | LRRK2 (0.67) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL1036038 | 0.77 | MAPK1 (0.52) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL30668734 | 0.77 | ROCK2 (1.00) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL20744117 | 0.77 | ROCK2 (1.00) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL19932612 | 0.77 | CCNK (0.44) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL29736567 | 0.77 | CCNK (0.44) | LRRK2ROCK2ROCK1CDC42BPBCDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-11-27 | — | — | US | disclosed |
| EP-4536657-A1 | LATS INHIBITORS AND USES THEREOF | The USA, as represented by The Secretary, Department of Health and Human Services (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | LATS2, LATS1, AKT1S1 | LRRK2 41/4885ROCK2 868/4885ROCK1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.